As part of a clinical study, the Early Clinical Trial Unit (ECTU) at NCT/UCC Dresden tested the cancer immunotherapy IMA401 for the first time in patients with advanced solid tumors. IMA401 is a ...

A team led by researchers from the National Center for Tumor Diseases (NCT/UCC) Dresden at the Carl Gustav Carus University Hospital (UKD) and the Carl Gustav Carus Faculty of Medicine at the TUD ...

As Legend’s LB2102 trial in SCLC fails to dazzle, co-developer Novartis banks on quick manufacturing to find a commercial ...

New and updated clinical data to be presented from over 30 patients across systemic lupus erythematosus (SLE) and rheumatoid ...

Repeat dosing of DeltExTM Drug Resistant Immunotherapy (DRI) had a median progression-free survival (mPFS) of 13.0 months and ...

AMGN wins EU approval for Imdylltra in extensive-stage small cell lung cancer after phase III data showed a 40% reduction in ...

The ASCO Annual Meeting is the world’s most prominent scientific gathering in the clinical oncology community, showcasing cutting-edge research in clinical oncology and advanced cancer therapies. This ...

"ASCO26: BMS and J&J debut shining multiple myeloma data" was originally created and published by Pharmaceutical Technology, ...

Zoci Intracranial ORR -- Achieved a 62.5% confirmed intracranial overall response rate and nearly 69% best overall ...

Presentations at the 51st ONS Congress explained how oncology nurses can help patients navigate the often-bewildering terrain ...